Palbociclib

Evidence Level: L5

Predicted Indications: 4

Palbociclib

Pharmacist Assessment Report

Palbociclib: From Breast Cancer (Original Indication Not Recorded) to Hyperthyroidism

Note on selection: The prompt specifies using the first predicted indication (rank 1, hyperthyroidism). It has no supporting evidence, so this report also summarises the better-supported candidates (rheumatoid arthritis and myeloid leukaemia) where they inform the decision.

One-Sentence Summary

Palbociclib is a CDK4/6 inhibitor marketed in Australia as Ibrance (tablet), and the data compiled for this report do not record its approved indication text. The TxGNN model’s top-ranked prediction is hyperthyroidism (score 0.9944), but there are 0 clinical trials and 0 publications supporting it. Among lower-ranked predictions, myeloid leukaemia (4 early-phase trials, 20 publications) and rheumatoid arthritis (preclinical data, 1 case report, 1 cohort study) have more support.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report (the ARTG indication text is blank)
Predicted New Indication	Hyperthyroidism
TxGNN Prediction Score	0.9944
Evidence Level	L5 (model prediction only)
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Palbociclib is a selective CDK4/6 inhibitor, a class used in hormone receptor-positive, HER2-negative breast cancer. Blocking CDK4/6 arrests the cell cycle at the G1-to-S transition.

For hyperthyroidism, no mechanistic link has been identified. No trials or publications support CDK4/6 inhibition in thyroid overactivity. The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It should not be treated as evidence of benefit.

By contrast, two other predictions have a plausible rationale:

Myeloid leukaemia (rank 6): CDK6 is a key dependency in AML, particularly MLL- and NUP98-rearranged disease. Preclinical work shows synergy with venetoclax/azacitidine, menin inhibitors and LSD1 inhibition.
Rheumatoid arthritis (rank 2): CDK6 drives synovial fibroblast hyperplasia in mouse arthritis models, and one case report describes RA improvement in a breast cancer patient on palbociclib.

Clinical Trial Evidence

Currently no related clinical trials registered for hyperthyroidism.

For reference, trials registered for the better-supported prediction, myeloid leukaemia:

Trial Number	Phase	Status	Enrolment	Key Findings
NCT02310243	Phase 1/2	Unknown	50	Palbociclib monotherapy in MLL-rearranged acute leukaemias; no results provided
NCT03132454	Phase 1	Active, not recruiting	32	Palbociclib alone and with sorafenib, decitabine or dexamethasone in relapsed/refractory leukaemia
NCT05627232	Phase 1	Recruiting	24	Palbociclib pre-treatment then CPX-351 in relapsed/refractory AML
NCT03878524	Phase 1	Terminated	2	Precision-oncology platform trial; minimal informative value

Literature Evidence

Currently no related literature available for hyperthyroidism.

For reference, selected publications for the better-supported predictions:

PMID	Year	Type	Journal	Key Findings
33587021	2021	Case report	Mod Rheumatol Case Rep	RA improved in a breast cancer patient treated with palbociclib
40504547	2025	Cohort	Oncologist	Immune-mediated diseases in breast cancer patients on CDK4/6 inhibitors plus endocrine therapy
39940918	2025	Preclinical	Int J Mol Sci	CDK6-dependent synovial hyperplasia in arthritic mice
36076608	2022	Preclinical	Biomed Pharmacother	Palbociclib enhances venetoclax plus azacitidine activity in AML
38890447	2024	Preclinical	Leukemia	Menin plus kinase inhibitors effective in NUP98-rearranged leukaemia
38430306	2024	Case report	Cancer Chemother Pharmacol	Palbociclib with venetoclax and azacitidine in refractory therapy-related AML

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 12818P	Ibrance	Tablet 75 mg	Not available in the compiled data

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (CDK4/6 inhibitor)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions; neutropenia and bone marrow suppression are recognised effects of the class
Emetogenicity Classification	Please refer to the PI
Monitoring Items	Full blood count; please refer to the PI for further monitoring
Handling Protection	Please refer to the PI

Safety Considerations

Drug Interactions: 100 interactions were identified (DDInter). Examples include:
- Major: clarithromycin, cobicistat, deferiprone, samarium (153Sm) lexidronam
- Moderate: aprepitant, dexamethasone, cimetidine, simvastatin, saxagliptin, cilostazol, among others
- Minor: prucalopride
Class safety signals: Pharmacovigilance analyses report thromboembolic events, interstitial lung disease and pulmonary toxicity with CDK4/6 inhibitors.

No warnings or contraindications were available from the label data. Please refer to the TGA-approved Product Information (PI) for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction, hyperthyroidism, rests on a model score alone, with no trials, no literature and no mechanistic link. Label-based safety data were also unavailable. Myeloid leukaemia (L3) and rheumatoid arthritis (L4) are more credible research questions than the top-ranked hyperthyroidism prediction.

To proceed, the following is needed:

Retrieve the TGA Product Information (approved indication, warnings, contraindications)
Obtain detailed mechanism-of-action data
For hyperthyroidism: any mechanistic or experimental evidence before further consideration
Consider re-prioritising the evaluation toward myeloid leukaemia (await results from the Phase 1/2 trials) and rheumatoid arthritis (needs prospective clinical data)
Check Australian trial registrations (ANZCTR) for relevant studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.